Schistosoma mansoni - NZ rabbit-model: resistance due to infection and active immunization with adult worm antigen

Almeida, Marília Sirianni dos Santos; Pinto, Roberto Magalhães; Noronha, Dely; Tendler, Míriam; Katz, Naftale

doi:10.1590/s0074-02761987000800043

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The analyses were stratified based on the measurement of frequencies of worm burdens within vaccinated animal populations as compared with non-vaccinated infected controls, as opposed to evaluation of mean values of parasite loads, as usually adopted. A solid base of pre-clinical data was generated establishing the immunization protocols that would be adopted during the following steps of the development [23,24,25,26,27,28,29,30,31].…”

Section: Innovative Strategies Adopted For Antigen Discovery and Ementioning

confidence: 99%

Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine

et al. 2018

Self Cite

View full text Add to dashboard Cite

Schistosomiasis, a disease historically associated with poverty, lack of sanitation and social inequality, is a chronic, debilitating parasitic infection, affecting hundreds of millions of people in endemic countries. Although chemotherapy is capable of reducing morbidity in humans, rapid re-infection demonstrates that the impact of drug treatment on transmission control or disease elimination is marginal. In addition, despite more than two decades of well-executed control activities based on large-scale chemotherapy, the disease is expanding in many areas including Brazil. The development of the Sm14/GLA-SE schistosomiasis vaccine is an emblematic, open knowledge innovation that has successfully completed phase I and phase IIa clinical trials, with Phase II/III trials underway in the African continent, to be followed by further trials in Brazil. The discovery and experimental phases of the development of this vaccine gathered a robust collection of data that strongly supports the ongoing clinical phase. This paper reviews the development of the Sm14 vaccine, formulated with glucopyranosyl lipid A (GLA-SE), from the initial experimental developments to clinical trials including the current status of phase II studies.

show abstract

Section: Innovative Strategies Adopted For Antigen Discovery and Ementioning

confidence: 99%

Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…The analyses were stratified based on the measurement of frequencies of worm burden distribution of vaccinated-challenged animal population over non-vaccinated infected controls, as opposed to evaluation of mean values of parasite loads, as usually adopted. A solid base of preclinical data was raised establishing the immunization protocols that would be adopted on the following steps of the development[23][24][25][26][27][28][29][30][31].…”

mentioning

confidence: 99%

Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine

Tendler

Almeida

Vilar

et al. 2018

Preprint

Self Cite

View full text Add to dashboard Cite

Schistosomiasis, a disease historically associated with poverty, lack of sanitation and social inequalities, is a chronic, debilitating parasitic infection, affecting hundreds of millions of people in endemic countries. Although schistosomiasis control approach has shown that chemotherapy is capable of reducing morbidity in humans, rapid re-infection is a reminder that the impact of drug treatment on transmission control or elimination initiatives is marginal. In addition, and regardless of more than two decades of well-executed control activities based on large-scale chemotherapy, the disease is expanding in many areas including Brazil. The development of the Sm14/GLA-SE schistosomiasis vaccine is an emblematic open knowledge innovation that has successfully completed Phase I and Phase IIa clinical trials, with Phase II/III trials underway in the African continent and to be followed in Brazil. Discovery and experimental phases were long term achievements leading to a robust collection of data that are strongly supporting the presently ongoing Clinical Phase. This paper reviews the development of the Sm14 vaccine formulated with GLA-SE (Glucopyranosyl Lipid A), from the earlier experimental developments to clinical trials including the recent status of Phase II studies.

show abstract

Arthropod and Helminth Parasites

Hofing¹,

Kraus²

1994

The Biology of the Laboratory Rabbit

View full text Add to dashboard Cite

Schistosoma mansoni - NZ rabbit-model: resistance due to infection and active immunization with adult worm antigen

Cited by 6 publications

References 0 publications

Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine

Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine

Current Status of the Sm14/GLA-SE Schistosomiasis Vaccine: Overcoming Barriers and Paradigms towards the First Anti-Parasitic Human(itarian) Vaccine

Arthropod and Helminth Parasites

Contact Info

Product

Resources

About